Filing Flows › Collegium Pharmaceutical (COLL) › Guidance & outlook
Collegium Pharmaceutical (COLL) guidance and outlook
Collegium Pharmaceutical (COLL) reaffirmed its guidance on Nov 5, 2026: EBITDA $445M–$470M for FY2026. Collegium Pharmaceutical's 10-Q filed Nov 5, 2026 makes 7 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $825M–$855M | new |
| EBITDA | FY2026 | $445M–$470M | reaffirmed |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- These valuations are based on management's estimates of economic and market conditions, including expected cash flows, costs and expenses, discount rates, tax rates and other market-participant assumptions.
- Any adjustments not based on facts and circumstances existing at the acquisition date, or if subsequent to the conclusion of the measurement period, will be recorded to our consolidated statements of operations.
- We believe that our cash and cash equivalents as of September 30, 2026 , together with expected cash inflows from operations, will enable us to fund our operating expenses, debt service, and capital expenditure requirements under our current business plan for the foreseeable future.
- We believe that our cash and cash equivalents as of September 30, 2026, together with expected cash inflows from operations, will enable us to fund our operating expenses, debt service, and capital expenditure requirements under our current business plan for the foreseeable future.
- • expected operating expenses to manufacture and commercialize our products and to operate our organization;
- • we exclude stock-based compensation expense from adjusted EBITDA although: (i) it has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy; and (ii) if we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would be…
- In July 2026, we entered into the One Lincoln Lease, which is expected to commence in the first quarter of 2027 and will have an initial term of eleven years (refer to Note 17, Commitments and Contingencies ).
Collegium Pharmaceutical's latest quarter
Collegium Pharmaceutical, Q3 2026: revenue $216M (+3% year over year), operating margin 13.3%, net earnings $21.8M, operating cash flow $86.5M. The chart follows the revenue to costs, profit and cash.
Questions
Did Collegium Pharmaceutical raise or lower its guidance?
Collegium Pharmaceutical (COLL) reaffirmed its guidance on Nov 5, 2026: EBITDA $445M–$470M for FY2026.
What does Collegium Pharmaceutical expect?
These valuations are based on management's estimates of economic and market conditions, including expected cash flows, costs and expenses, discount rates, tax rates and other market-participant assumptions. Any adjustments not based on facts and circumstances existing at the acquisition date, or if subsequent to the conclusion of the measurement period, will be recorded to our consolidated statements of operations. We believe that our cash and cash equivalents as of September 30, 2026 , together with expected cash inflows from operations, will enable us to fund our operating expenses, debt ser
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.